Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872233 | 0.98 | NAAA (0.54) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL5871733 | 0.91 | ALDH1A1 (0.56) | NAAATSHREPHX1HCAR2ALDH1A1 | |
| SCHEMBL1269101 | 0.85 | NAAA (0.55) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL4448631 | 0.85 | NAAA (0.55) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL7359498 | 0.83 | NAAA (0.52) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL8970879 | 0.83 | NAAA (0.52) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL6050206 | 0.82 | NAAA (0.52) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL425031 | 0.81 | NAAA (0.60) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL3635010 | 0.81 | HCAR2 (0.41) | NAAATSHRHCAR2ALDH1A1LMNA | |
| SCHEMBL2357674 | 0.80 | NAAA (0.59) | NAAATSHREPHX1HCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | NAAA 1079/4885TSHR 2365/4885EPHX1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.